25.90
1.25 (5.07%)
| Penutupan Terdahulu | 24.65 |
| Buka | 25.49 |
| Jumlah Dagangan | 976,992 |
| Purata Dagangan (3B) | 938,011 |
| Modal Pasaran | 1,198,553,600 |
| Harga / Pendapatan (P/E Ke hadapan) | 9.67 |
| Harga / Jualan (P/S) | 1.74 |
| Harga / Buku (P/B) | 1.57 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2025 |
| Margin Keuntungan | -14.20% |
| Margin Operasi (TTM) | 15.77% |
| EPS Cair (TTM) | -2.15 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 3.30% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -35.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 82.08% |
| Nisbah Semasa (MRQ) | 2.40 |
| Aliran Tunai Operasi (OCF TTM) | 189.39 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 163.38 M |
| Pulangan Atas Aset (ROA TTM) | 3.90% |
| Pulangan Atas Ekuiti (ROE TTM) | -12.08% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Menurun | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | Pacira BioSciences, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.88 |
|
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 1.77% |
| % Dimiliki oleh Institusi | 107.04% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 65.00 (HC Wainwright & Co., 150.97%) | Beli |
| Median | 32.00 (23.55%) | |
| Rendah | 24.00 (Barclays, -7.34%) | Beli |
| Purata | 40.33 (55.71%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 25.53 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 08 Apr 2025 | 65.00 (150.97%) | Beli | 26.27 |
| 28 Feb 2025 | 70.00 (170.27%) | Beli | 24.05 | |
| Needham | 08 Apr 2025 | 32.00 (23.55%) | Beli | 26.27 |
| 28 Feb 2025 | 32.00 (23.55%) | Beli | 24.05 | |
| Barclays | 28 Feb 2025 | 24.00 (-7.34%) | Beli | 24.05 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |